Last reviewed · How we verify
Budesonide CFC
Budesonide is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs.
Budesonide is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs. Used for Asthma (maintenance and prevention), Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Budesonide CFC |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Budesonide is an inhaled corticosteroid that reduces airway inflammation by activating glucocorticoid receptors, leading to decreased production of inflammatory mediators and recruitment of immune cells. The CFC formulation refers to the chlorofluorocarbon propellant used in the metered-dose inhaler delivery system. It is used to prevent and control asthma symptoms and reduce airway hyperresponsiveness.
Approved indications
- Asthma (maintenance and prevention)
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Muscle cramps
- Throat irritation
Key clinical trials
- Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma (PHASE3)
- Utilization Patterns of Pulmicort in Real Life Practice
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide CFC CI brief — competitive landscape report
- Budesonide CFC updates RSS · CI watch RSS
- AstraZeneca portfolio CI